In patients who completed the phase III studies on @mg and had an actual ( last ) dose of @mg during weeks @-@ of the extension Maintenance Period ( n = @ ) , median percent change in seizure frequency per @days improved from -@ % ( phase III Maintenance Period ) to -@ % ( weeks @-@ extension Maintenance Period ) ; @ % responder rates were @ % and @ % .